Inhibikase Therapeutics

(NASDAQ) IKT

Current Price$1.62

Market Cap$215.21M

Since IPO (2020)-97%

5 Year-95%

1 Year-17%

1 Month-19%

Inhibikase Therapeutics Financials at a Glance

Market Cap

$215.21M

Revenue (TTM)

$0.00

Net Income (TTM)

-$50.96M

EPS (TTM)

-$0.43

P/E Ratio

-3.75

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$1.62

Volume

627,330

Open

$1.68

Price

$1.62

Volume

627,330

Open

$1.68

Previous Close

$1.63

Daily Range

$1.61 - $1.69

52-Week Range

$1.33 - $2.26

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$1.62

Volume

627,330

Open

$1.68

Previous Close

$1.63

Daily Range

$1.61 - $1.69

52-Week Range

$1.33 - $2.26

Estimated Earnings Date

Aug 13, 2026

IKT News

Inhibikase Posts Wider Loss in Q2

Motley Fool Markets TeamAug 14, 2025

IKT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inhibikase Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Mark T. Iwicki, MBA

Website

www.inhibikase.com

Headquarters

Atlanta, GA 30339, US

IKT Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-40%

Return on Capital

-33%

Return on Assets

-29%

Earnings Yield

-26.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$215.21M

Shares Outstanding

132.03M

Volume

627.33K

Avg. Volume

1.10M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$51.97M

EBITDA

-$53.29M

Operating Cash Flow

-$27.79M

Capital Expenditure

-$13.40K

Free Cash Flow

-$27.79M

Cash & ST Invst.

$178.76M

Total Debt

$0.00

Inhibikase Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$215.21M

N/A

Market Cap/Employee

$14.35M

N/A

Employees

N/A

Net Income

-$16.38M

-19.8%

EBITDA

-$18.22M

-15.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$170.37M

+83.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-29.40%

N/A

Return on Invested Capital

-33.17%

N/A

Free Cash Flow

-$12.06M

-193.9%

Operating Cash Flow

-$12.06M

-193.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SRZNSurrozen, Inc.

SRZNSurrozen, Inc.$21.52-11.73%

TTRXTurn Therapeutics Inc.

TTRXTurn Therapeutics Inc.$5.28-8.09%

AGENAgenus Inc.

AGENAgenus Inc.$3.23-4.86%

GLSIGreenwich LifeSciences, Inc.

GLSIGreenwich LifeSciences, Inc.$22.25-6.00%

CGTXCognition Therapeutics, Inc.

CGTXCognition Therapeutics, Inc.$1.29-5.15%

EXOZeXoZymes, Inc.

EXOZeXoZymes, Inc.$9.34-0.11%

ENTXEntera Bio Ltd.

ENTXEntera Bio Ltd.$1.18-3.28%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$14.38-0.13%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.13-0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.19+0.14%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.14-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.50+0.02%

QQQInvesco QQQ Trust

QQQInvesco QQQ Trust$705.06-0.05%

MRVLMarvell Technology

MRVLMarvell Technology$263.47-0.17%

Questions About IKT

What is the current price of Inhibikase Therapeutics?

Inhibikase Therapeutics is trading at $1.63 per share.

What is the 52-week range for Inhibikase Therapeutics?

Over the past 52 weeks, Inhibikase Therapeutics has traded between $1.33 and $2.26.

How much debt does Inhibikase Therapeutics have?

As of the most recent reporting period, Inhibikase Therapeutics reported total debt of $0.00.

How much cash does Inhibikase Therapeutics have on hand?

Inhibikase Therapeutics reported $49.57M in cash and cash equivalents in its most recent financial results.

What is Inhibikase Therapeutics’s dividend yield?

Inhibikase Therapeutics does not currently have a dividend yield.

Inhibikase Therapeutics

Inhibikase Therapeutics Financials at a Glance

IKT News

Inhibikase Posts Wider Loss in Q2

IKT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Inhibikase Therapeutics

IKT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Inhibikase Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IKT

What is the current price of Inhibikase Therapeutics?

What is the 52-week range for Inhibikase Therapeutics?

How much debt does Inhibikase Therapeutics have?

How much cash does Inhibikase Therapeutics have on hand?

What is Inhibikase Therapeutics’s dividend yield?

Premium Investing Services